Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) Stock Price, Quote & AI Analysis

Live BDRX stock price, real-time charts, AI-powered analysis, technical analysis, earnings insights, and market sentiment for Biodexa Pharmaceuticals plc American Depositary Shs.

TradeVae provides AI-driven analysis and real-time market intelligence for Biodexa Pharmaceuticals plc American Depositary Shs (BDRX), including price action, technical indicators, earnings performance, analyst sentiment, and risk-aware market context.

B
BDRX
Biodexa Pharmaceuticals plc American Depositary Shs
real-time
$0.00 +0.00 (+0.00%)
Open
3.280000
High
3.280000
Low
3.170000
Volume
1,690
VWAP
-
Market Cap
$2,139,436.20
52W Range
$2.86 - $96.50
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Biodexa Pharmaceuticals plc American Depositary Shs's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Biodexa Pharmaceuticals plc American Depositary Shs Overview

Company information

Company Overview

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Company Details
Market Cap
$1.43M
Shares Outstanding
451,636
Weighted Shares Outstanding
648,314
CEO
Stephen Anthony Stamp
Employees
11
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and indicators

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Biodexa Pharmaceuticals plc American Depositary Shs Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...